Liguo Chi
Overview
Explore the profile of Liguo Chi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
209
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liang W, Sagar S, Ravindran R, Najor R, Quiles J, Chi L, et al.
Nat Commun
. 2023 Aug;
14(1):5031.
PMID: 37596294
Mitochondrial quality control is critical for cardiac homeostasis as these organelles are responsible for generating most of the energy needed to sustain contraction. Dysfunctional mitochondria are normally degraded via intracellular...
2.
Liang W, Diao R, Quiles J, Najor R, Chi L, Woodall B, et al.
bioRxiv
. 2023 Feb;
PMID: 36824711
Mitochondrial quality control is critical for cardiac homeostasis as these organelles are responsible for generating most of the energy needed to sustain contraction. Dysfunctional mitochondria are normally degraded via intracellular...
3.
Zhu S, Chen Z, Zhu M, Shen Y, Leon L, Chi L, et al.
Circ Heart Fail
. 2021 Jun;
14(6):e008289.
PMID: 34129362
Background: Cardiomyopathy is a major clinical feature in Barth syndrome (BTHS), an X-linked mitochondrial lipid disorder caused by mutations in (), encoding a mitochondrial acyltransferase required for cardiolipin remodeling. Despite...
4.
Yadav V, Chi L, Zhao R, Tourdot B, Yalavarthi S, Jacobs B, et al.
J Clin Invest
. 2019 Apr;
129(7):2872-2877.
PMID: 30990798
Deep vein thrombosis (DVT), caused by alterations in venous homeostasis is the third most common cause of cardiovascular mortality; however, key molecular determinants in venous thrombosis have not been fully...
5.
Anyanwu A, Kanthi Y, Fukase K, Liao H, Mimura T, Desch K, et al.
Arterioscler Thromb Vasc Biol
. 2019 Mar;
39(4):e118-e129.
PMID: 30816804
Objective- Leukocyte flux contributes to thrombus formation in deep veins under pathological conditions, but mechanisms that inhibit venous thrombosis are incompletely understood. Ectonucleotide di(tri)phosphohydrolase 1 ( ENTPD1 or Cd39), an...
6.
Chi L, Belardinelli L, Zeng A, Hirakawa R, Rajamani S, Ling H, et al.
Am J Physiol Heart Circ Physiol
. 2016 Mar;
310(10):H1313-20.
PMID: 26993228
Late Na(+) current (INaL) is enhanced in myocytes of animals with chronic heart failure and patients with hypertrophic cardiomyopathy. To define the role of INaL in diastolic heart failure, the...
7.
Fryer R, Ng K, Chi L, Jin X, Reinhart G
J Pharmacol Toxicol Methods
. 2015 May;
74:26-32.
PMID: 25946685
Introduction: ICH guidelines, as well as best-practice and ethical considerations, provide strong rationale for use of telemetry-instrumented dog colonies for cardiovascular safety assessment. However, few studies have investigated the long-term...
8.
Liles J, Hoyer K, Oliver J, Chi L, Dhalla A, Belardinelli L
J Pharmacol Exp Ther
. 2015 Mar;
353(3):480-9.
PMID: 25770134
Pulmonary arterial hypertension (PAH) is a progressive disease that often results in right ventricular (RV) failure and death. During disease progression, structural and electrical remodeling of the right ventricle impairs...
9.
Burashnikov A, Di Diego J, Sicouri S, Doss M, Sachinidis A, Barajas-Martinez H, et al.
Eur J Heart Fail
. 2014 Jan;
16(3):271-80.
PMID: 24464846
Aims: Heart failure (HF) is associated with development of AF and life-threatening ventricular tachycardia and fibrillation (VT/VF). Vulnerability to development of AF and VT/VF at different stages of HF and...
10.
Fryer R, Harrison P, Muthukumarana A, Nodop Mazurek S, Ng K, Chen R, et al.
J Cardiovasc Pharmacol
. 2011 Dec;
59(4):369-76.
PMID: 22179024
The strategic integration of in vivo cardiovascular models is important during lead optimization to enable a wide therapeutic index for cardiovascular safety. However, under what conditions (eg, species, route of...